Lexicon Pharmaceuticals (LXRX) Non-Current Deffered Revenue (2010 - 2019)

Lexicon Pharmaceuticals (LXRX) has 10 years of Non-Current Deffered Revenue data on file, last reported at $24.3 million in Q2 2019.

• On a quarterly basis, Non-Current Deffered Revenue rose 33.38% year-over-year to $24.3 million in Q2 2019; TTM through Jun 2019 was $24.3 million, a 33.38% increase from a year earlier, with the FY2018 full-year figure at $23.7 million, down 5.03% from the prior year.
• Non-Current Deffered Revenue for Q2 2019 stood at $24.3 million, down from $24.6 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for LXRX reached as high as $109.2 million in Q4 2015 and fell as low as $11.7 million in Q1 2015.
• Historically, Non-Current Deffered Revenue has averaged $38.1 million across 5 years, with a median of $24.8 million in 2017.
• Across the five-year window, Non-Current Deffered Revenue jumped 777.17% in 2016 and sank 72.01% in 2017, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $109.2 million in 2015, then plunged by 55.17% to $48.9 million in 2016, then slumped by 49.11% to $24.9 million in 2017, then slipped by 5.03% to $23.7 million in 2018, then advanced by 2.61% to $24.3 million in 2019.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $24.3 million in Q2 2019, $24.6 million in Q1 2019, and $23.7 million in Q4 2018.